Endocrine Abstracts

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient parathyroid hormone levels in the blood, low serum calcium and elevated serum phosphate. Studies evaluating the prevalence of chronic hypoparathyroidism (cHypoPT) are limited, and it is challenging to compare prevalence estimates owing tothe rarity of the disease and the difficulty of differentiating transient from permanent or cHypoPTin secondary data analyses. PublishedcHypoPTprevalence is between ...

Despite conventional treatment with oral calcium and active vitamin D, patients with chronic hypoparathyroidism (cHypoPT) can remain not adequately controlled (NAC) and have abnormal biochemistry, disease complications, or symptoms impacting quality of life. A systematic literature review (SLR) was conducted to evaluate the clinical burden for patients with cHypoPT, with an emphasis on patients with NAC disease. This abstract focuses on data related to renal and cardiovascular...

The Hypoparathyroidism Symptom Diary (HypoPT-SD) was developed for the daily assessment of key symptoms and impact of HypoPT as reported by patients with chronic HypoPT and includes 13-items: a 7-item Symptom subscale, 4-item Impact subscale, and single-item anxiety and depression scores. The current analysis was undertaken to confirm test-retest reliability and construct validity of HypoPT SD Symptom subscale scores using data collected during two open-label, single-arm studi...

In Europe, rhPTH(1-84) is an approved adjunctive treatment for adults with chronic hypoparathyroidism that cannot be adequately controlled with conventional therapy. Here we present data from the longest rhPTH(1-84)-treated study cohort of patients with hypoparathyroidism. In a single-centre, single-arm, phase 4 study (NCT02910466), long-term rhPTH(1-84) treatment (25, 50, 75, or 100 μg/day subcutaneously) was evaluated in adults with chronic hypoparathyroidism who mainta...

Chronic hypoparathyroidism is a rare mineral homeostasis disorder managed by conventional therapy (oral calcium and active vitamin D), alone or with adjunctive rhPTH(1-84). Chronic hypoparathyroidism is associated with considerable symptom burden, which can interfere with daily living. We report results from a web-based, cross-sectional survey conducted among adults with chronic hypoparathyroidism. The objectives were to quantify the impact on overall life interference of (1) ...

This study investigated risk of cardiovascular (CV) events over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients who did not receive rhPTH(1––84). The rhPTH(1–84)-treated patient cohort was derived from the NCT00732615 (REPLACE), NCT01...

Changes in estimated glomerular filtration rate (eGFR) over 5 years were evaluated in adult patients with chronic hypoparathyroidism. A cohort of patients treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), was derived from NCT01297309 (RACE) and NCT01199614 (HEXT) clinical trials. A historical control patient cohort with hypoparathyroidism who did not receive rhPTH(1–84) or rhPTH(1&#...

This study evaluated risk of chronic kidney disease (CKD) outcomes over a period of up to 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone (1–84), rhPTH(1–84), compared with a historical control cohort of patients who did not receive rhPTH(1–84). The cohort of patients with chronic hypoparathyroidism treated with rhPTH(1–84) was de...